Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and/or prevention of pain and/or inflammation.

The present invention provides a transdermal patch including: a backing layer; a drug-containing adhesive layer including rivastigmine or a pharmaceutically acceptable salt thereof and two kinds of skin penetration enhancers; and a release liner; wherein the drug-containing adhesive layer is disposed between the backing layer and the release liner; a content of rivastigmine or the pharmaceutically acceptable salt thereof is between 10 wt % and 30 wt % based on a total weight of the drug-containing adhesive layer; and the adhesive includes a pressure sensitive adhesive.

The present disclosure relates to the transdermal administration of cannabidiol (CBD) for the reduction of seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).

The present invention aims to provide a vaccine pharmaceutical composition universally usable for induction of cellular immunity against various antigens and exerting a high cellular immunity inducing effect. The present invention relates to a vaccine pharmaceutical composition for inducing cellular immunity, containing: an antigen; and a first cellular immunity induction promoter that is a bisphosphonate.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of an active agent comprising an active agent-containing layer structure, said active agent-containing layer structure comprising A) a backing layer, B) an active agent-containing layer comprising a therapeutically effective amount of the active agent, and C) a skin contact layer comprising at least one silicone acrylic hybrid polymer.

A method for producing a gel patch comprising an adhesive mass layer on a backing fabric, comprising a step of applying a composition comprising a physiologically active substance, a water-soluble polymer, glycerin, and water to the backing fabric to form the adhesive mass layer, wherein a loss tangent of the composition in dynamic viscoelasticity measurement at 1 Hz at a time of application to the backing fabric is 0.75 to 1.

Transdermal delivery systems for the systemic delivery of memantine are described, wherein the system comprises a drug reservoir layer and an adhesive layer, optionally together with one or more intermediate and/or supporting layers, wherein the drug reservoir layer comprises an acrylate polymer or copolymer, a permeation enhancer, a carrier, and memantine base generated in situ by reaction of a memantine salt and an alkaline salt. Compositions and kits comprising the various components, e.g., drug reservoir and/or adhesive compositions are described. Methods relating to treatment of CNS disorders, e.g., Alzheimer's disease and/or dementia, using the aforementioned transdermal delivery devices and/or compositions are also described.

The purpose of the present invention is to provide a rivastigmine-containing transdermal absorption preparation having high adhesion to the skin and capable of continuously administering rivastigmine over a long period of time. A transdermal absorption preparation has rivastigmine, a rubber polymer, a tackifier resin, and a polymer compound having a nitrogen-containing group.

A transdermal absorption preparation precursor 50 containing a release liner 10 containing one first valley fold part 1, one or two first mountain fold parts 2, and a first base line L1 and a second base line L2 on one side and the other side apart from the first valley fold part 1 as a line of demarcation and at an approximately equal distance from the first valley fold part 1, wherein at least one of the first base line L1 and the second base line L2 is a fold line of the first mountain fold part 2, and a drug-containing layer 3 having a center line laid on the first base line L1 and an adhesive layer 4 having a center line laid on the second base line L2 on the release liner 10.

The invention related to a one-pot process of making a single-phase silicone-acrylic hybrid adhesive composition comprising acrylic polymer and silicone polymer that are covalently bonded through a SiOSi linkage. The acrylic polymer contains at least one hydrolyzable silane (meth)acrylic monomer or siloxane (meth)acrylic macromer. These functional moieties provide reaction sites to form SiOSi bond by reacting hydrolyzable groups in the silicone polymer in the presence of a base or acid catalyst and water. The formed covalent bonds between the two incompatible systems of silicone polymer and acrylic polymer prevents phase separation and thereby a permanent, homogeneous single-phase system is formed.